MRNA January 2026 Options Begin Trading

StockOptionsChannel highlights two option strategies on Moderna (MRNA $29.41): selling a $26 put (bid $1.15) would obligate purchase at $26 with an effective cost basis of $24.85, is ~12% out‑of‑the‑money and currently modeled at a 70% chance of expiring worthless, yielding a 4.42% return on cash committed (32.29% annualized) if it does. Alternatively, selling a $33 covered call (bid $1.18) against existing shares commits sale at $33 (≈12% upside) and would produce a 16.22% total return if called at the January 2026 expiration, with a 59% modeled chance to expire worthless and a 4.01% (29.29% annualized) premium boost if it does. Implied volatilities are elevated (put 91%, call 83%) versus trailing 12‑month realized volatility of 67%, and StockOptionsChannel will track and publish changing odds and contract histories—underscoring yield‑enhancement opportunities but also the tradeoff between income and capped upside or forced entry.

Analysis

The article outlines two income-oriented option strategies on Moderna (MRNA), with the stock trading at $29.41. Selling a $26 put at a $1.15 bid would obligate purchase at $26 and reduces effective cost basis to $24.85 (before commissions); that strike is ~12% out-of-the-money and Stock Options Channel models a 70% probability the put expires worthless, producing a 4.42% return on cash committed (32.29% annualized) if it does.

On the call side, selling a $33 covered call with a $1.18 bid against shares bought at $29.41 commits sale at $33 and yields a 16.22% total return if assigned at the January 2026 expiration; the call is ~12% out-of-the-money with a 59% modeled chance to expire worthless, producing a 4.01% premium boost (29.29% annualized) if it does.

Implied volatilities are elevated (put 91%, call 83%) versus trailing 12‑month realized volatility of 67%, indicating option premiums are rich and compensation for risk; Stock Options Channel plans to track changing odds and contract histories, so investors should monitor IV, modeled probabilities and be explicit about willingness to be assigned or to cap upside given biotech sensitivity and potential for sudden moves.

Key Decisions for Investors

• Consider selling the $26 cash‑secured put only if you are willing to own MRNA at an effective cost basis of $24.85 and size the position to accept potential assignment,
• If already long MRNA, consider selling the $33 covered call to generate a 4.01% premium boost and a 16.22% capped return to Jan 2026, but be prepared to forfeit upside above $33 if the stock rallies,
• Monitor implied volatility (puts 91%, calls 83%) versus realized vol (67%) and the Stock Options Channel odds charts; if IV rises further, premiums increase but so does tail risk—adjust position size or hedge accordingly,
• Use limit orders and predefine roll or exit plans given modeled probabilities (70% put expiry, 59% call expiry) and avoid overconcentration in a single biotech exposure